Loading...
XSHG
603718
Market cap665mUSD
Dec 05, Last price  
7.18CNY
1D
1.70%
1Q
0.70%
Jan 2017
-59.71%
IPO
53.09%
Name

Shanghai Hile Bio-Technology Co Ltd

Chart & Performance

D1W1MN
XSHG:603718 chart
P/E
27.50
P/S
17.37
EPS
0.26
Div Yield, %
0.40%
Shrs. gr., 5y
0.44%
Rev. gr., 5y
-0.51%
Revenues
271m
+12.59%
260,127,200310,842,908318,792,688285,272,025316,577,603343,338,733303,650,205254,565,186277,992,965259,128,542347,289,178299,991,674240,722,981271,039,818
Net income
171m
+172.28%
107,273,400112,545,779118,789,524101,221,38795,402,61585,536,349113,739,53221,298,2230053,856,680121,607,84962,870,202171,180,295
CFO
46m
P
149,608,100122,475,830147,626,205110,218,481201,687,364108,388,16734,920,78318,917,48259,251,287167,682,48943,632,976292,905,014-2,938,20946,473,090
Dividend
Jul 19, 20240.0287 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces, and sells veterinary biological products for livestock and poultry in China. The company offers swine fever live vaccines; trivalent inactivated vaccines for piglets; inactivated vaccine for streptococcus suis; pseudorabies live vaccines; inactivated oil emulsion vaccine of porcine parvovirus disease; pathogenic porcine reproductive and respiratory syndrome live vaccines; transmissible gastroenteritis, porcine epidemic diarrhea, and porcine rotavirus triple live vaccines; porcine reproductive and respiratory syndrome live vaccines; swine transmissible gastroenteritis and swine epidemic diarrhea combined inactivated vaccines; porcine circovirus type 2 inactivated vaccines; and swine Japanese encephalitis live vaccines. It also provides chicken infectious bursal disease live vaccines; inactivated avian infectious rhinitis vaccines; newcastle disease and avian influenza combined inactivated vaccines; newcastle disease, infectious bronchitis, egg drop syndrome, and avian influenza quadruple inactivated vaccines; avian influenza inactivated vaccines; newcastle disease, infectious bronchitis, and avian influenza triple inactivated vaccines; avian infectious bronchitis live vaccines; avian newcastle disease and avian infectious bronchitis combined live vaccines; newcastle disease low virulent live vaccines; Marek's disease turkey herpes virus live vaccines; and fowlpox live vaccines. The company was founded in 1981 and is based in Shanghai, China.
IPO date
May 15, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT